Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiplex targeted chimeric antigen receptor CAR-T cell therapy - Cellevolve/ Seattle Childrens Therapeutics

Next Previous
X
Search
Drug Profile

Multiplex targeted chimeric antigen receptor CAR-T cell therapy - Cellevolve/ Seattle Childrens Therapeutics

Alternative Names: SC-CAR4BRAIN

Latest Information Update: 26 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellevolve
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I CNS cancer

Most Recent Events

  • 26 Mar 2023 Seattle Children's Hospital plans a phase I trial for Diffuse intrinsic pontine glioma, Diffuse midline glioma and CNS tumours (In children, In adolescents, In adults, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05768880)
  • 07 Dec 2022 Phase-I clinical trials in CNS cancer (In adolescents, In adults, In children, In infants, Recurrent) in USA (unspecified route) (Cellevolve pipeline, December 2022)
  • 09 Mar 2022 Cellevolve and Seattle Childrens Therapeutics agree to co-develop CAR T cell therapeutics in USA for CNS cancers

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top